Jefferies puts Alkermes on hold

Alkermes, Inc. was given a hold rating by Jefferies & Co., Inc. analyst David Windley. The company's Vivitrol sales forecast of $35 million to 45 million was a concern as it suggests a much shallower launch trajectory. Without near-term pipeline-related catalysts, Jefferies keeps its hold rating and maintains its $22.50 target. Shares of the Cambridge, Mass., pharmaceutical company were up 27 cents, or 1.37%, at $19.93 on volume of 3,161,113 shares versus the three-month running average of 1,693,390 shares. (Nasdaq: ALKS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.